Press release
Investigation announced for Investors who lost money with shares of PepGen Inc. (NASDAQ: PEPG) over possible Violations of Securities Laws
An investigation for investors in PepGen Inc. (NASDAQ: PEPG) shares over potential securities laws violations by PepGen Inc.
Investors who purchased shares of PepGen Inc. (NASDAQ: PEPG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by PepGen Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Boston, MA based PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
Shares of PepGen Inc. (NASDAQ: PEPG) declined from $19.30 per share on July 29, 2024, to as low as $7.73 per share on August 14, 2023.
Those who purchased shares of PepGen Inc. (NASDAQ: PEPG) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of PepGen Inc. (NASDAQ: PEPG) over possible Violations of Securities Laws here
News-ID: 3655530 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of PepGen Inc. (NASDAQ …
An investigation was announced for current long-term investors in shares of PepGen Inc. (NASDAQ: PEPG) concerning potential breaches of fiduciary duties by certain directors of PepGen Inc.
Investors who are current long term investors in PepGen Inc. (NASDAQ: PEPG) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: PEPG…
Novo Nordisk A/S (NYSE: NVO) Investor Alert: Lawsuit alleges False and Misleadin …
An investor, who purchased shares of Novo Nordisk A/S (NYSE: NVO), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Novo Nordisk A/S in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and for certain investors are short and strict deadlines running. Deadline: September 30,…
Lawsuit filed for Investors who lost money with shares of PubMatic, Inc. (NASDAQ …
An investor, who purchased shares of PubMatic, Inc. (NASDAQ: PUBM), filed a lawsuit over alleged violations of Federal Securities Laws by PubMatic, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of PubMatic, Inc. (NASDAQ: PUBM) have certain options and for certain investors are short and strict deadlines running. Deadline: October 20, 2025. NASDAQ: PUBM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Reckitt Benckiser Group plc (OTC: RBGLY) Long Term Investor Alert: Investigation …
An investigation on behalf of current long-term investors in shares of Reckitt Benckiser Group plc (OTC: RBGLY) concerning potential breaches of fiduciary duties was announced.
Investors who are current long term investors in Reckitt Benckiser Group plc (OTC: RBGLY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in OTC: RBGLY…
More Releases for PepGen
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myotonic Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Myotonic Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Investors who lost money with shares of PepGen Inc. (NASDAQ: PEPG) should contac …
An investor, who purchased shares of PepGen Inc. (NASDAQ: PEPG), filed a lawsuit over alleged violations of Federal Securities Laws by PepGen Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of PepGen Inc. (NASDAQ: PEPG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 8, 2025. NASDAQ: PEPG investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Myotonic Dystrophy Pipeline Analysis and Clinical Trials Assessment, 2025 by Del …
Myotonic Dystrophy Pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analyzes DelveInsight.
Myotonic Dystrophy Overview:
Myotonic Dystrophy (DM) is the most prevalent form of adult-onset muscular dystrophy and falls under the category of myopathies. It exists in two primary forms: type I (DM1 or Steinert disease) and the milder type II (DM2 or proximal myotonic myopathy). Both are progressive, multisystem genetic disorders.
Symptoms vary widely, from no…
Duchenne Muscular Dystrophy Pipeline Insights 2024: Therapies, Clinical Trials, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Duchenne Muscular Dystrophy pipeline constitutes 75+ key companies continuously working towards developing 75+ Duchenne Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Duchenne Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Duchenne Muscular…
Myotonic Dystrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Myotonic Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Myotonic Dystrophy Pipeline Insight, 2023" report…
Global Peptide Drug Conjugate Clinical Trial Market 360-Degree Research with Cur …
Peptide drug conjugates (PDCs) are a novel class of therapeutics that combine the specificity and efficacy of peptides with the pharmacological properties of small molecule drugs. PDCs consist of a peptide conjugated to a small molecule drug through a linker molecule. The linker molecule is designed to be stable in the bloodstream but cleavable in the target tissue, allowing the drug to be released at the site of action. PDCs…
